Mallinckrodt Pharmaceuticals Declares Its Independence — Again

barbara.lempert ST. LOUIS, June 28, 2013 (ST. LOUIS POST DISPATCH)–In his offices overlooking Mallinckrodt Pharmaceuticals’ sprawling campus in Hazelwood, chief executive ...

Raptor Pharmaceutical’s Procysbi Receives Positive Recommendation From CHMP

barbara.lempert Raptor Pharmaceutical’s PROCYSBI(TM) Receives Positive Recommendation From CHMP NOVATO, Calif., June 28, 2013 (GLOBE NEWSWIRE) — Raptor Pharmaceutical ...

Omthera Pharmaceuticals Announces Termination Of Antitrust Waiting Period

barbara.lempert PRINCETON, N.J., June 27, 2013 /PRNewswire/ — Omthera Pharmaceuticals, Inc. (NASDAQ: OMTH) today announced that, as of June 26, 2013, the Federal Trade Commission ...

Imprimis Pharmaceuticals, Inc. set to join Russell Microcap Index

barbara.lempert SAN DIEGO, June 27, 2013 /PRNewswire/ — Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY), which is focused on the commercialization of compounded drug formulations, ...

Peregrine Pharmaceuticals Provides Update on Bavituximab Clinical Program

barbara.lempert Company Strengthens Cash Position as It Prepares to Initiate Phase III Trial in Second-Line NSCLC by Year-End While Partnering Discussions Continue; Recent Data Supporting ...

AMAG Pharmaceuticals Campaign Wants Patients to Know “Iron Matters”

barbara.lempert    Nationwide Survey Underscores Need for Greater Understanding                      of the Importance of Iron LEXINGTON, Mass., June 24, 2013 ...

Momenta Pharmaceuticals Announces Issuance of U.S. Patent for Sialylation Technology

barbara.lempert CAMBRIDGE, Mass., June 25, 2013 (GLOBE NEWSWIRE) — Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and ...

Anthera Pharmaceuticals Announces Receipt of Nasdaq Notice

barbara.lempert HAYWARD, Calif., June 21, 2013 /PRNewswire/ — Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH) (the “Company”), a biopharmaceutical company focused on ...

Idenix Pharmaceuticals Announces Update on Development Program for Its Lead HCV Nucleotide Prodrug Candidate, IDX20963

barbara.lempert CAMBRIDGE, Mass., June 20, 2013 (GLOBE NEWSWIRE) — Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development ...

Bellus Health to Acquire Thallion Pharmaceuticals

barbara.lempert LAVAL, QC, June 18, 2013 – BELLUS Health Inc. (TSX: BLU) (“BELLUS Health”) and Thallion Pharmaceuticals Inc. (“Thallion”) (TSXV: TLN) ...

Oramed Pharmaceuticals Announces Withdrawal of Proposed Underwritten Public Offering

barbara.lempert JERUSALEM June 21, 2013 – Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (www.oramed.com), a developer of oral drug delivery systems, announced today that it has  ...

Progenics Pharmaceuticals Announces Pricing of Public Offering of Common Stock

barbara.lempert TARRYTOWN, N.Y., June 20, 2013 (GLOBE NEWSWIRE) — Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) announced today the pricing of an underwritten public offering ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS